论文部分内容阅读
最尖端的科研成果,在癌症的临床诊断和治疗上即将取得成果。1987年9月在东京召开的第46届日本癌症学会总会上,相继介绍了运用分子、细胞水平的免疫学新疗法;为了克服以往化学疗法的副作用,应用了生物工程学;NMR(核磁共振)、激光等诊断技术也将用于临床。一、新免疫疗法的出现一位74岁女患1983年做了乳腺癌手术后再次复发,并转移到肺和肝,伴有晚期癌症所特有的腹膜炎症状。使用新疗法,癌症的阴影消失而痊愈。这是高知医大藤本重义教授开发的CTL(癌细胞障碍性淋巴细胞)疗法的结果。即每隔10天给患者静脉注射50万个杀伤T 细胞,但机体内还有一种抑制性T 细胞,干扰杀伤T 细胞过分增殖。CTL 疗法是把具有选择性地杀伤抑制性T 细胞的抗癌剂注射给患者后再注射杀伤T 细胞的一种治癌方法。CTL 疗法是从患者的血液中提取淋巴细胞与患者的癌细胞相混合后于体外培养。其特点是选择性地增
The most advanced scientific research results will soon achieve results in the clinical diagnosis and treatment of cancer. At the 46th Japan Cancer Society General Conference held in Tokyo in September 1987, new methods of immunology using molecular and cellular levels were introduced; in order to overcome the side effects of previous chemotherapy, bioengineering was applied; NMR (nuclear magnetic resonance) ), laser and other diagnostic techniques will also be used clinically. First, the emergence of new immunotherapy A 74-year-old female patient recurred after breast cancer surgery in 1983, and transferred to the lungs and liver, accompanied by peritonitis symptoms unique to advanced cancer. With the new therapy, the shadow of cancer disappears and heal. This is the result of the CTL (Cancer Cell Disordered Lymphocyte) therapy developed by Professor Takashi Fujimoto. That is, intravenous injection of 500,000 killer T cells to patients every 10 days, but there is also an inhibitory T cell in the body, which interferes with the excessive proliferation of killer T cells. CTL therapy is a cancer treatment method that injects anticancer agents that selectively kill suppressor T cells into patients before injecting killer T cells. CTL therapy is the in vitro culture of lymphocytes extracted from the patient’s blood and mixed with the patient’s cancer cells. Its characteristics are selectively increased